Categories
News

kidney disease market Size, Status, Global Outlook 2020 To 2027

The kidney disease market is expected to reach US$ 133,444.71 million by 2027 from US$ 81,128.11 million in 2019. The market is estimated to grow with a CAGR of 6.5% from 2020 to 2027.

Request Sample Copy Of this Report @ https://www.theinsightpartners.com/sample/TIPRE00014589/

Policy-makers have to ensure that an appropriate mix of pharmaceutical policy options is implemented to meet equitable, affordable, and sustainable access to medicines as well as medical care. The World Health Organization has projected various strategies to support policy-makers in developing suitable policies, including the concept of the vital medicine list and the universal health coverage (UHC) approach. Moreover, European countries with advanced UHC and social protection systems have developed pharmaceutical pricing and reimbursement systems that intend to offer various crucial medicines to their citizens at no or reduced cost. For instance, Armenia ensures 100% reimbursement for medicines for specific diseases such as TB, mental health diseases, diabetes, and chronic kidney failure.

 

Kidney Disease Market– by Product Type

  •      Diagnosis
    •     Blood Tests
    •     Urine Tests
    •     Imaging Tests
    •     Others
  •   Treatment
    •   Drug Class
      •   ACE Inhibitors
      •   Angiotensin-II Receptor Blockers
      •   Diuretics
      •   Others

 

In May 2019, VELTASSA, a prescription medication used to treat high potassium levels in the blood (hyperkalemia), has secured reimbursement in Germany, after the completion of AMNOG process (price negotiation and arbitration process). Moreover, reimbursement for the drug was secured in Finland, Austria, Portugal, Spain, Belgium, and a favorable recommendation was received from the National Institute for Health and Care Excellence in the UK. Furthermore, at the end of 2019, VELTASSA was launched in Sweden, Norway, Denmark, Belgium, Germany, Spain, The Netherlands, and Austria. Besides, in 2018, Vifor Pharma announced a licensing agreement with Zeria Pharmaceutical Co., Ltd. to catalyze the process of VELTASSA’s regulatory and reimbursement approval in Japan. Further, in December 2019, China’s National Healthcare Security Administration (NHSA) included Roxadustat in the updated National Reimbursement Drug List (NRDL). The drug Roxadustat is included in the NRDL for the treatment of anemia in CKD (Chronic Kidney Disease). Such lucrative reimbursement policies are likely to accelerate the growth of the market during the forecast period.

Purchase Copy of this Report @   https://www.theinsightpartners.com/buy/TIPRE00014589/

Market Insights

High Prevalence of Chronic Diseases Leading to Kidney Diseases

Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. Moreover, according to a study published by National Kidney Foundation in 2020, around 35.0% of the diabetic population above age 20 years would develop chronic kidney disease over the period of time.

As per the data published by National Kidney Foundation Inc., in 2020, CKD is likely to cause more deaths than prostate cancer or breast cancer. It is an under-recognized emergency health condition among people. 1 in 3 American adults (about 80 million people) is at risk due to CKD.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact:

Call: +1-646-491-9876

Email: [email protected]